A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Urothelial Carcinoma|Carcinoma, Non-Small Cell Lung|Small Cell Lung Carcinoma|Triple Negative Breast Carcinoma|Hepatocellular Carcinoma
Interventions: DRUG: Atezolizumab
Sponsor: Hoffmann-La Roche